JP4928079B2 - 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 - Google Patents

慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 Download PDF

Info

Publication number
JP4928079B2
JP4928079B2 JP2004555563A JP2004555563A JP4928079B2 JP 4928079 B2 JP4928079 B2 JP 4928079B2 JP 2004555563 A JP2004555563 A JP 2004555563A JP 2004555563 A JP2004555563 A JP 2004555563A JP 4928079 B2 JP4928079 B2 JP 4928079B2
Authority
JP
Japan
Prior art keywords
group
rejection
substituted
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004555563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514013A5 (enExample
JP2006514013A (ja
Inventor
ジョン エム． ウィリアムズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2006514013A publication Critical patent/JP2006514013A/ja
Publication of JP2006514013A5 publication Critical patent/JP2006514013A5/ja
Application granted granted Critical
Publication of JP4928079B2 publication Critical patent/JP4928079B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004555563A 2002-11-21 2003-11-21 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 Expired - Fee Related JP4928079B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42833202P 2002-11-21 2002-11-21
US60/428,332 2002-11-21
PCT/US2003/037318 WO2004047825A1 (en) 2002-11-21 2003-11-21 Use of diamide derivatives for inhibiting chronic tissue transplant rejection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010210237A Division JP2010280725A (ja) 2002-11-21 2010-09-17 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用

Publications (3)

Publication Number Publication Date
JP2006514013A JP2006514013A (ja) 2006-04-27
JP2006514013A5 JP2006514013A5 (enExample) 2007-01-11
JP4928079B2 true JP4928079B2 (ja) 2012-05-09

Family

ID=32393386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004555563A Expired - Fee Related JP4928079B2 (ja) 2002-11-21 2003-11-21 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用
JP2010210237A Withdrawn JP2010280725A (ja) 2002-11-21 2010-09-17 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010210237A Withdrawn JP2010280725A (ja) 2002-11-21 2010-09-17 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用

Country Status (9)

Country Link
US (2) US7687530B2 (enExample)
EP (1) EP1567138B1 (enExample)
JP (2) JP4928079B2 (enExample)
AT (1) ATE493980T1 (enExample)
AU (1) AU2003291134A1 (enExample)
DE (1) DE60335652D1 (enExample)
ES (1) ES2363914T3 (enExample)
PT (1) PT1567138E (enExample)
WO (1) WO2004047825A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259691B2 (en) 2000-05-12 2006-02-16 Genzyme Corporation Modulators of TNF-alpha signaling
PT1562571E (pt) * 2002-11-21 2011-11-25 Genzyme Corp Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
EP1567138B1 (en) * 2002-11-21 2011-01-05 Genzyme Corporation Use of a diamide derivative for inhibiting chronic transplant rejection
EP1718768B1 (en) 2004-01-21 2012-05-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
JP2008537875A (ja) 2005-03-14 2008-10-02 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 固形臓器移植レシピエントにおいて移植片生着を評価するための方法および組成物
EP2631301B1 (en) * 2008-08-18 2017-10-11 The Board of Trustees of the Leland Stanford Junior University Methods for determining a graft tolerant phenotype in a subject
US9938579B2 (en) 2009-01-15 2018-04-10 The Board Of Trustees Of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
US9290813B2 (en) 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
EP2550371A4 (en) 2010-03-25 2013-11-20 Univ Leland Stanford Junior PROTEIN AND GENE BIOMARKERS FOR EXTRACTING ORGAN TRANSPLANTS
WO2012139051A2 (en) 2011-04-06 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for iga nephropathy
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc COMPOSITION AND METHODS FOR CELLULAR MODULATION
WO2017142879A1 (en) * 2016-02-16 2017-08-24 The Regents Of The University Of California Methods for immune system modulation with microporous annealed particle gels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087849A2 (en) * 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf- alpha signaling

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5861382A (en) 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0663836B1 (en) 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
US6030615A (en) 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE4430127A1 (de) 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
DE4430128A1 (de) 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
JPH11501289A (ja) * 1994-12-02 1999-02-02 藤沢薬品工業株式会社 Ｎｏ介在疾患の予防および／または治療のためのペプチド化合物
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
ATE259235T1 (de) 1995-07-20 2004-02-15 Cell Eng Ag Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene
IL115245A (en) 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
NZ322565A (en) * 1995-11-22 1999-11-29 Darwin Discovery Ltd Mercaptoalkykpeptidyl compounds having an imidazole substitutent and their use as inhibitors of matrix metalloproteinases and tumor necrosis factor
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
PT942740E (pt) 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998039026A2 (en) 1997-03-07 1998-09-11 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US5801193A (en) 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6229878B1 (en) * 1998-01-21 2001-05-08 Lucent Technologies, Inc. Telephone answering method and apparatus
US6359061B1 (en) * 1999-03-19 2002-03-19 Isis Pharmaceuticals, Inc. Amide compound libraries
CA2366264A1 (en) 1999-04-02 2000-10-12 Bristol-Myers Squibb Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
MXPA02011376A (es) 2000-05-22 2004-02-26 Leo Pharma As Benzofenonas como inhibidores de il-1beta y tnf-alfa.
WO2004003154A2 (en) 2002-06-26 2004-01-08 The Trustees Of Columbia Uninersity In The City Of New York Use of streptavidin to inhibit transplant rejection
PT1562571E (pt) * 2002-11-21 2011-11-25 Genzyme Corp Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
EP1567138B1 (en) * 2002-11-21 2011-01-05 Genzyme Corporation Use of a diamide derivative for inhibiting chronic transplant rejection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087849A2 (en) * 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf- alpha signaling

Also Published As

Publication number Publication date
US7687530B2 (en) 2010-03-30
US20100256211A1 (en) 2010-10-07
DE60335652D1 (de) 2011-02-17
US20040163654A1 (en) 2004-08-26
ATE493980T1 (de) 2011-01-15
AU2003291134A1 (en) 2004-06-18
PT1567138E (pt) 2011-04-11
JP2010280725A (ja) 2010-12-16
JP2006514013A (ja) 2006-04-27
ES2363914T3 (es) 2011-08-19
EP1567138A1 (en) 2005-08-31
WO2004047825A1 (en) 2004-06-10
EP1567138B1 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
JP2010280725A (ja) 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用
AU716514B2 (en) Use of rapamycin derivatives in vasculopathies and xenotransplantation
JP4004070B2 (ja) １，３―プロパンジオール誘導体の新しい用途
US20090023712A1 (en) Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
EA026456B1 (ru) Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
US7678822B2 (en) Induction of immune tolerance
RS60264B1 (sr) Novo heterociklično jedinjenje
JPH08507514A (ja) 脳血管性疾患を治療または予防するための薬物
JP2021107447A (ja) 移植片拒絶反応の処置方法
CA2607325A1 (en) The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders
JPS62190123A (ja) 免疫抑制剤
BRPI0617252A2 (pt) regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
KR100616020B1 (ko) 맥관장애및이종이식술에서의라파마이신유도체의용도
HK1018688B (en) Use of rapamycin derivatives in vasculopqthies and xenotransplantation
JPWO2004063201A1 (ja) 統合失調症治療剤
JP2005504009A (ja) 心臓保護のためのアデノシンａ１／ａ２アゴニストの投与のタイミングおよび継続
HK40000009A (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120117

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120210

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150217

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4928079

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees